Lv0
0 积分 2023-07-21 加入
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
7小时前
已完结
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
7小时前
已完结
Harnessing CD3 diversity to optimize CAR T cells
1年前
已完结
Antigen Selection for Enhanced Affinity T-Cell Receptor–Based Cancer Therapies
1年前
已完结
First soluble TCR therapy opens ‘new universe’ of cancer targets
1年前
已完结
CAR T therapy beyond cancer: the evolution of a living drug
1年前
已完结
Unraveling barriers to iPSC-derived CAR-T cell differentiation
1年前
已完结
Clinical implications of T cell exhaustion for cancer immunotherapy
1年前
已完结
Personalized cancer vaccines pass first major clinical test
1年前
已完结
Trends in the approval of cancer therapies by the FDA in the twenty-first century
1年前
已完结
皖公网安备34019202002308
